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ecently, a growing body of clinical data has shown that the ﬁrst generation of drug-eluting stents
1st-gen DES) implantation could elicit coronary conduit artery vasomotor dysfunction at nonstented
eference segments as late as 12 months after implantation compared with that seen with bare-metal
tents. The mechanism of this phenomenon is still not fully understood. Pathological studies have im-
licated delayed arterial healing and poor re-endothelialization after the 1st-gen DES implantation.
iven the vast use of DES globally, a thorough understanding of the early and long-term safety of these
evices is paramount. Therefore, this article systematically reviews the current clinical, pathophysiological,
nd histopathological available data regarding 1st-gen DES-associated vascular endothelial dysfunction.
eanwhile, we will also review the newer generation of DES and emerging endothelial-friendly technology.
J Am Coll Cardiol Intv 2009;2:1169–77) © 2009 by the American College of Cardiology Foundationi
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nevelopment and widespread utilization of drug-
luting stents (DES) has provided a novel and
fficacious treatment for coronary artery disease
CAD), allowing for localized elution of neointi-
al inhibiting drugs, thereby reducing in-stent
estenosis and target lesion revascularization rates
ompared with bare-metal stents (BMS) (1,2).
owever, numerous reports have suggested in-
reased incidences of late stent thrombosis (LST)
nd very LST with the first-generation drug-
luting stent (1st-gen DES), especially after dis-
ontinuation of dual antiplatelet therapy (3–5).
Although many factors such as patient, lesion, as
ell as procedural characteristics are likely contrib-
tory, clinical, histopathological, and pathophysi-
logical studies have implicated that delayed arte-
ial healing and poor re-endothelialization may
lay a major role in the pathogenesis of LST (6,7).
ore recently, a variety of studies have also re-
orted that 1st-gen DES sirolimus-eluting
Cypher, Cordis Corporation, Miami Lakes, Flor-
rom the *Department of Cardiology, University of Louisville, Louis-
ille, Kentucky; and the †Saint Joseph’s Research Institute, Saint Joseph’s
ospital of Atlanta, Georgia. Dr. Yin is currently affiliated with the 1st
ffiliated Hospital of Harbin Medical University (HMU), China.h
anuscript received September 1, 2009; revised manuscript received
eptember 30, 2009, accepted October 7, 2009.da) and paclitaxel-eluting (TAXUS, Boston Sci-
ntific Corporation, Natick, Massachusetts) stents
licited focal endothelium-dependent vasomotor
ysfunction in both proximal and distal nonstented
eference segments (NSRS) of coronary arteries for
to 12 months post-stent implantation (8–12).
The endothelium is a monolayer organ with
utocrine, paracrine, and endocrine functions. Un-
er healthy conditions, endothelial cells (ECs)
roduce many vasoactive substances, which main-
ain vascular homeostasis and normal vasomotor
one (13,14). Nitric oxide (NO), a key factor
enerated by ECs, is associated with inhibition of
latelet and leukocyte activation, and maintenance
f vascular smooth muscle in a nonproliferative
tate. In addition to being the main determinant of
asal vascular smooth muscle tone, NO opposes
he actions of potent endothelium-derived con-
racting factors such as angiotensin-II and endo-
helin (ET)-1 (15–18). Impairment of NO bioac-
ivity or bioavailability and/or imbalance between
ndothelium-derived relaxing and contracting fac-
ors is crucial in the mechanisms of endothelial
ysfunction (ED). The pathophysiological hall-
arks of dysfunctional endothelium include vascu-
ar inflammation, thrombogenesis, as well as ab-
ormal vasomotor function. Indeed, many studies
ave demonstrated that ED is an independent
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1170redictor for cardiovascular disease (19–22). In the coronary
ed, ED could cause vessel spasm, which leads to reduced
yocardial perfusion and myocardial ischemia. However,
D also has been shown to enhance the vulnerability of
laque lesion and subsequent likelihood of plaque rupture
23). Higo et al. (24) reported sirolimus-eluting stents
SES) promoting the formation of atherosclerotic yellow
eointima in the stent-implanted lesion at 10 months
ollow-up. This intense yellow appearance has been
ommonly observed in patients with an advanced athero-
sclerotic plaque (25).
There are many tools to deter-
mine the integrity of vasomotor
function in response to physiologi-
cal and pharmacological stimuli.
Acetylcholine (Ach) evokes a NO-
mediated vasodilatory response in
healthy arteries via muscarinic en-
dothelial membrane receptors, but
this effect is blunted, and paradoxi-
cal vasoconstriction may be ob-
served with ED (26,27). Quantita-
tive coronary angiography after
intracoronary (IC) Ach infusion is
currently one of the most utilized
invasive methods for the evaluation
of vasomotor dysfunction after
DES implantation (9,11). There-
fore, in the current article, we will
systematically review the available
clinical as well as pathophysiological
and histopathological data on
DES-associated ED. Mean-
while, the newer generation DES
(namely, 2nd-gen) and novel future
emerging endothelial-friendly tech-
nology are also discussed.
SES and Coronary ED
Sirolimus is a macrolide antibiotic
that binds to the cytosolic receptor
FKBP12 and inhibits down-
regulation of the cyclin-dependent
inase inhibitor p27kip1, thereby inhibiting vascular smooth
uscle cell (SMC) proliferation and migration (28).
xperimental studies. The effects of sirolimus on endothe-
ial function in vitro are summarized in Tables 1 and 2. This
ompound has been reported to inhibit not only SMC
roliferation but also endothelial regeneration in vitro.
ohacsi et al. (29) reported sirolimus inhibition of growth
actor-induced proliferation of both cultured EC and SMC.
n their in vitro porcine coronary artery model, Jeanmart et
bbreviations
nd Acronyms
ch  acetylcholine
ES  biolimus-eluting
tent(s)
MS  bare-metal stent(s)
AD  coronary artery
isease
ES  drug-eluting stent(s)
C  endothelial cell
D  endothelial dysfunction
ES  everolimus-eluting
tent(s)
NOS  endothelial nitric
xide synthase
PC  endothelial progenitor
ell
T  endothelin
C  intracoronary
ST  late stent thrombosis
O  nitric oxide
SRS  nonstented
eference segment(s)
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
MC  smooth muscle cell
ES  zotarolimus-eluting
tent(s)
st-gen DES  first-generation
rug-eluting stentl. (30) observed severe impairment of relaxant responses to oerotonin and bradykinin in epicardial arteries exposed to
irolimus, suggesting a direct adverse effect of sirolimus on
ndothelial function. Through deactivation of the p70 S6
inase pathway, an essential step in cell cycle progression in
esponse to growth factors, sirolimus exerts inhibition on
C proliferation (31). More recent data indicate that
irolimus may also affect the growth and differentiation of
ndothelial progenitor cells (EPCs) (32).
Using a large clinically relevant animal model, we inves-
igated endothelial function in vitro using an organ chamber
ensiometry in coronary artery segments distal to polymer-
oated BMS, and SES at 1 month after implantation (33).
istal conduit arteries devoid of direct mechanical injury
emonstrated vasomotor dysfunction in SES, but not BMS
r polymer stents. Increased contractile and endothelium-
ndependent relaxation responses, as well as reduced
ndothelium-dependent relaxation, were also noted even
eyond duration of nearly complete drug release. We,
herefore, hypothesized that even though SES showed
ffective neointimal inhibition, the eluted drug and durable
olymer can also adversely affect vasomotor function of
ownstream coronary segments.
linical studies. Table 3 summarizes clinical studies evalu-
ting SES and endothelial function. The normal response to
ncreased flow in coronary conductance vessels is vasodila-
ion, due to stimulation of endothelial NO synthesis and
elease in response to shear stress. If paradoxical vasocon-
triction occurs, there is likely underlying damaged endo-
helium or abnormal endothelial function. In their first
ublished clinical study, Togni et al. (10) studied exercise-
nduced coronary vasodilatory function in patients with
nown CAD after DES implantation. Using biplane quan-
itative coronary angiography at rest and during supine
icycle exercise, 25 patients were assessed at 6  1 month
fter percutaneous coronary intervention. Eleven patients
eceived BMS (control group) and 14 received SES (DES
roup). Coronary segments proximal and distal to the stent
howed anticipated exercise-induced vasodilation in the
ontrol BMS arm. The percentage diameter changes were
15  3% and 17  4% for proximal and distal
egments, respectively. In contrast, exercise-induced vaso-
onstriction of the proximal and distal vessel segments
djacent to SES was clearly noticed (2  4% and 15 
%, respectively; p  0.001 vs. corresponding segments of
ontrol subjects). Sublingual nitroglycerin was associated
ith maximal vasodilation in both groups. The authors
oncluded that BMS does not affect physiological response
o exercise proximal and distal to the stent. This indicates
hat in atherosclerotic arteries stented with BMS the vaso-
otor recovers quickly, while SES is clearly associated with
xercise-induced paradoxical vasoconstriction at the same
ollow-up time point. Similarly, Hofma et al. (9) reported
bnormal coronary vasoconstrictive responses to IC infusion
f Ach after SES implantation. The investigators prospec-
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1171ively studied 15 patients undergoing stenting for a single de
ovo lesion. Endothelial function was assessed at baseline
nd 6 months post-intervention. Significantly more vaso-
onstriction was observed distal to stented segment for SES
n comparison with BMS. More recently, Fuke et al. (11)
lso reported similar coronary vasomotor dysfunction with
C infusion of Ach 6 months after SES implantation in 35
atients with stable angina. The coronary vasomotor func-
ion was evaluated by Obata et al. (12) at 2 weeks post-stent
mplantation (SES vs. BMS), following successful reperfu-
ion therapy after acute myocardial infarction. In the SES
roup, more severe constriction of distal epicardial coronary
rteries in response to Ach was evidenced compared with that
een in the BMS patients. The authors further found coronary
lood flow and vascular endothelial growth factor levels were
lso significantly diminished for SES than BMS. The authors
oncluded that, in the initial phase of acute myocardial infarc-
ion, SES implantation adversely affects endothelium-
Table 1. Pre-Clinical Studies Evaluating Endothelial Function After DES Imp
Author (Ref. #)
(Year) Stent Type
Number (Type)
of Animals Methods Fo
Pendyala et al.
(37) (2009)
PES
BMS
Naive
12 (swine) Organ chamber
Substance P
A23187
SNP
1
Li et al. (33)
(2008)
SES
BMS
9 (swine) Organ chamber
Substance P
A23187
SNP
1
Jabs et al. (45)
(2008)
Sirolimus continuous
infusion
34 (Wistar rats) Organ chamber
Acetylcholine
SNP
7
Long et al. (43)
(2007)
Rapamycin or FK506 NA (mice) Organ chamber
Acetylcholine
SNP
2
Jeanmart et al.
(30) (2002)
Rapamycin 28 (swine) Organ chamber
Serotonin
Bradykinin
A23187
SNP
4
BMS bare-metal stent(s); DES drug-eluting stent(s); PES paclitaxel-eluting stent(s); SES siro
Table 2. Pre-Clinical Studies Evaluating Endothelial Function After DES Imp
Author (Ref.#)
(Year) Stent Type
Number (Type)
of Animals Methods Follow-Up
Pendyala et al.
(37) (2009)
PES
BMS
Naive
12 (swine) Substance P
NTG
1month 15
Miyauchi et al.
(2008)*
CES
BMS
6 (swine) Bradykinin
NTG
1month 5 m
Shinke et al.
(2008)†
PES
BMS
9 (swine) Substance P
NTG
1month 15
*MiyauchiK, Kasai T, YokayamaT, et al. Effectivenessof statin-elutingstentonearly inflammatory respons
incidence of intramural thrombus after overlapping paclitaxel-eluting stents: correlated angioscopic anCES cerivastatin-eluting stent(s); NTG nitroglycerine; other abbreviations as in Table 1.ependent vasomotor function in both resistance and epicar-
ial coronary arteries, with associated reduction in myocardial
ascular endothelial growth factor secretion.
All of the studies noted in the preceding text have
oncluded that SES implantation produced a vasoconstric-
ive response in coronary segments proximal and/or distal to
he stent during coronary provocative test, whereas BMS
id not. These clinical results indeed were confirmed and
nderscored by pre-clinical in vitro physiology organ cham-
er findings that the SES impairs endothelial function at
SRS in coronary conduit arteries.
aclitaxel-Eluting Stents (PES) and Coronary ED
aclitaxel binds specifically to the beta-tubulin subunit of
icrotubules and appears to antagonize the disassembly of
his key cytoskeletal protein; this action results in accumu-
tion In Vitro
p Study Vessel
Endothelial-Dependent
Vasomotor Function
Endothelial-Independent
Vasomotor Function
Coronary rings 15
mm proximal and
distal to the stent
Impaired in PES both at
proximal and distal
segments compared
with BMS and naive
Normal
Coronary rings 15
mm distal to the
stent
Impaired in SES distal
segment compared
with BMS
Normal
Aortic rings Impaired relaxation Impaired relaxation
Aortic rings Impaired relaxation Normal
Coronary rings Impaired relaxation Normal
luting stent(s); SNP sodium nitroprusside.
tion In Vivo
rence Vessel
Endothelial-Dependent
Vasomotor Function
Endothelial-Independent
Vasomotor Function
roximal and distal
stent
Impaired in PES both at proximal
and distal segments compared
with BMS and naive
Normal
ly distal to the Normal endothelial function in
both groups
Normal
roximal and distal
stent
Impaired in PES both at proximal
and distal segments compared
with BMS
Normal
eointimal thickness inaporcinecoronarymodel. Circ J2008;72:832–8.†ShinkeT, Li J, ChenJP, et al.High
athologic analysis in porcine coronary arteries. Circ Cardiovasc Intervent 2008;1:28–35.lanta
llow-U
month
month
days
0 min
8 hlanta
Refe
mm p
to the
m on
stent
mm p
to the
eandn
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1172ation of microtubule bundles and aberrant microtubular-
erived structures in the mitotic phase of the cell cycle (34).
xperimental studies. Tables 1 and 2 summarize the pre-
linical studies evaluating endothelial function after PES.
y in vitro cell assay, Axel et al. (35) demonstrated that
igh-dose paclitaxel is a potent inhibitor of not only SMC,
ut also EC proliferation and migration. Similarly, Farb et
l. (36) have revealed a dose-dependent decrease in neoin-
imal formation and subsequent increase in vessel wall
oxicity from paclitaxel.
Using both in vivo and in vitro methods in our laboratory,
endyala et al. (37) performed the first systematic evaluation
f vasomotor function of coronary epicardial arteries both at
roximal and distal NSRS, as well as in perfusion bed
ntramyocardial resistance arteries, after overlapping PES
mplantation in laboratory swine. We also analyzed the
nflammatory response at overlapped regions and superoxide
nion (O2
·) production at both proximal and distal NSRS.
he results demonstrated that while PES is effective in
nhibiting neointimal growth, a profound adverse effect on
asomotor function was observed in both conduit and
esistance arteries distant from the site of direct mechanical
njury. Such widespread influence on vasomotor function
Table 3. Clinical Studies Evaluating Endothelial Function After DES Implan
Author (Ref. #) (Year) Stent Type Patients Methods Follow-Up
Kim et al. (40) (2008) SES
PES
BMS
85 Acetylcholine
NTG
6 months
Hamilos et al. (55) (2008) PES
SES
BES
ZES
BMS
83 Right atrial
pacing
NTG
9–12 months
Shin et al. (56) (2008) SES
ZES
23 Acetylcholine
NTG
6–9 months
Hamilos et al. (58) (2008) SES
BES
34 Right atrial
pacing
NTG
9  1 month
Togni et al. (38) (2007) PES
BMS
27 Exercise NTG 6  2 months
Shin et al. (39) (2007) PES
SES
BMS
23 Acetylcholine
NTG
6–9 months
Obata et al. (12) (2007) SES
BMS
29 Acetylcholine
NTG
2 weeks
post-AMI
Fuke et al. (11) (2007) SES
BMS
33 Acetylcholine
NTG
6 months
Hofma et al. (9) (2006) SES
BMS
12 Acetylcholine
NTG
6 months
Togni et al. (10) (2005) SES
BMS
25 Exercise
NTG
6  2 months
BES biolimus A9-eluting stent(s); NTG nitroglycerine; ZES zotarolimus-eluting stent(s); otherrom the stented locale appears to be associated with txtensive localized inflammation at the stent site, as well as
ncreased O2
· production in the proximal and distal NSRS.
eyond vasomotor dysfunction, this study also illustrated
ignificantly increased contractile response to PGF2 and
T-1 in both the proximal and distal NSRS for PES.
linical studies. Table 3 is a summary of clinical studies
valuating endothelial function after PES implantation.
wo recent clinical investigations demonstrated that PES
mplantation was associated with long-term coronary ED
hen compared with the BMS counterpart. Togni et al.
38), using exercise-induced flow-mediated vasodilation,
tudied 27 patients with CAD. They observed that PES
mplantation is associated with exercise-induced vasocon-
triction in the 10-mm peri-stent regions, suggesting ED as
he underlying mechanism. Improvement of vascular func-
ion occurred over time, indicating delayed vascular healing.
ersistent de-endothelialization by balloon angioplasty
arotrauma would not be expected in these regions; there-
ore, incomplete or even absent re-endothelialization is
ikely not responsible for this phenomenon.
Similarly, Shin et al. (39) studied endothelial function in
atients without 6-month angiographic evidence of reste-
osis after single BMS or DES (SES and PES) implanta-
eference Vessel
Segment
Endothelial-Dependent
Vasomotor Function
Endothelial-Independent
Vasomotor Function
proximal and
al to stent
Impaired in both SES and PES at
the distal segments
Normal
proximal and
al to stent
Impaired in both SES and PES at
both proximal and distal
segments, but not in BES,
ZES, and BMS
Normal
al and distal
10 mm)
r proximal and far
al (10–20 mm)
Impaired in SES group involving
distal and far distal segments
Normal
mm proximal and
al to stent
Impaired only in SES both
proximal and distal
Normal
mm proximal and
al to stent
Impaired both proximal and
distal to stent in PES
Normal
al and distal
10 mm)
proximal and distal
–20 mm)
Impaired only in distal and far
distal segment both PES
and SES
Normal
mm distal to stent Impaired only in SES at distal
segment
Normal
proximal and
al to stent
Impaired only in SES both
proximal and distal
Normal
mm distal to stent
y
Impaired only in SES both
proximal and distal
Normal
mm proximal and
al to stent
Impaired both proximal and
distal to stent in PES
Normal
iations as in Table 1.tation
R
5 mm
dist
10 mm
dist
Proxim
(5–
Nea
dist
5–15
dist
5–10
dist
Proxim
(5–
Far
(10
15–20
5 mm
dist
2–17
onl
5–10
distion. The authors reported that both SES (n  9) and PES
(
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1173n  8) groups demonstrated a similar pattern of abnormal
oronary vasoconstriction in response to Ach at the long
istal portion (distal and far distal segments) of the treated
essel (Fig. 1). However, endothelium-independent vasodi-
ation was preserved in all groups. These results suggested
hat SES or PES implantation may be associated with
oronary ED in remote portions of the treated vessel.
imilarly, in another recent study (40), both PES and SES
eployment resulted in greater endothelium-dependent va-
oconstriction than the BMS group at corresponding seg-
ents, while nitrate-induced endothelium-independent va-
odilation did not differ significantly.
ossible Mechanisms for the
st Gen DES-Induced ED
olecular mechanisms of vascular endothelial functional
mpairment after DES implantation remain incompletely
efined, but recent work has provided profound insight into
he potential etiologies of this complex phenomenon. Mul-
iple factors may be involved, including direct toxic effect
rom the entrapped drug and/or an acute or delayed hyper-
ensitivity reaction from the polymer and/or drug. As
hown, the vasa vasorum interna in porcine coronary arteries
riginating directly from the arterial lumen can extend over
everal centimeters along the coronary artery wall (41).
Figure 1. Examples of Coronary Angiogram With Endothelial Function Test
Coronary angiogram showed a marked vasoconstriction to incremental acetylc
(SES) (A) and paclitaxel-eluting stent (PES) (B) compared with those of the bar
ence nonstented artery.herefore, the antiproliferative drugs and vasoactive chem- lcals may locally diffuse through these tiny channels to the
SRS.
In a recent study (42) comparing the histology of the
bdominal aortas that were perfused with barium sulfate in
abbits 9 weeks after implantation of BMS or sirolimus
ES, there appears to be a correlation between the number
f vasa vasorum induced and the type of stent used and the
ctual healing process. After 9 weeks, the qualitative intras-
ent luminal diameter was fairly uniform in both the DES
nd the BMS. The thickness of neointima was similar in
oth groups. The number of vasa vasorum in the sirolimus
ES increased compared with that in the BMS (p  0.05).
n increased number of vasa vasorum produced by the DES
hen compared with the BMS shows a difference in
esponse to local vessel injury in rabbits. This result suggests
hat vasa vasorum may play a role in the persistent inflam-
ation generated by DES (42).
ES and ED. Long et al. (43), in a mice model, reported that
cute in vitro sirolimus treatment, as well as genetic deletion
f the sirolimus-receptor isoform FKBP12.6, increased
rotein kinase C-mediated endothelial nitric oxide synthase
eNOS) threonine 495 phosphorylation, thereby leading to
ecreased vascular NO production and subsequent ED.
hey demonstrated that displacement of FKBP12/12.6
rom endothelial ryanodine receptors resulted in intracellu-
o 9 Months After Stent Implantation
infusion, in particular in the segment distal to the sirolimus-eluting stent
al stent (BMS) (C) or mid-segments of the left circumﬂex artery as a refer-at 6 t
holine
e-metar Ca2 leakage, which in turn decreases NO production
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1174nd endothelium-dependent vasodilation. This observation
upports the findings of Takeda et al. (44) who reported
ecreased eNOS activity in aortic EC from rats treated with
K506 for 4 weeks. Similarly, Jabs et al. (45) showed that a
-day continuous infusion of sirolimus into Wistar rats
roduced a marked degree of ED. The investigators postu-
ated sirolimus-associated increases in vascular O2
· con-
entrations, with resultant loss of vascular NO bioavailabil-
ty by up-regulation of both mitochondrial O2
· release and
icotinamide adenine dinucleotide phosphate oxidase-driven
2
· production. Although the rat model was one of pro-
onged systemic exposure to sirolimus, the authors proposed
hat the same processes could contribute to the observed ED
oted after deployment of sirolimus-coated stents. There are
everal important limitations to this study. First, generalizabil-
ty of sirolimus dosing in the rat study to that of DES
mplantation in the human coronary artery is not established.
econdly, the attribution of sirolimus to long-term ED must
e tempered with the observation that vascular dysfunction
fter SES deployment persists long after the drug is gone. If
he compound is, in fact, the cause, this implies that its effect
ust persist beyond drug exposure. In the current experiment,
owever, the exposure of sirolimus continued to the end of the
tudy. Therefore, although both these studies indicated that
he drug may be contributory, the potential role of the polymer
annot be ruled out.
The Cypher stents contain a 5-m coating of the drug
irolimus combined with nonerodable polymers, covered
ith a layer of drug-free polymer to allow the drug gradual
elease. As most of the drug is eluted from the polymer
oating by 28 days (46) and fully eluted by 60 days (47), the
bnormal vasomotion observed at 6 months in the clinical
rials is likely not a direct effect of sirolimus itself. However,
he lingering effects of a persistent abnormality in endothe-
ial regeneration cannot be excluded. Alternatively, the
olymer from which the drug elutes, which may have
ontributed to a case of a marked hypersensitivity reaction
47), may have impaired vasomotion; however, this effect
lso remains speculative.
ES and ED. Aside from the metallic struts, PES contain 2
mportant components: nonbiodegradable synthetic poly-
er and paclitaxel. The polymer used in PES is highly
ipophilic such that only 10% of the initial drug dose is
luted from the current slow-release formulation of PES,
eaving the residual 90% in a tissue bound form (48,49). We
ecently reported (37) a significantly higher level of O2
· in
onduit arteries proximal and distal to PES, as compared
ith that seen for BMS and naive vessels. Due to chroni-
ally increased production of reactive oxygen species, NO
ioavailability may be decreased, resulting in impairment of
ndothelium-mediated vascular relaxation response. Thus,
nderlying direct drug toxicity and/or polymer incompati-
ility and potentiation of superoxide activity may be culprit
echanisms in ED. Beyond vasorelaxation impairment, our eata also illustrated significantly increased contractile re-
ponse to PGF2 and ET-1 in both the proximal and distal
SRS for PES.
In general, the 1st-gen DES have shown to enhance
asoconstriction when compared with BMS. This lower set
oint for contraction might be anticipated to cause adverse
ffects on distal myocardial perfusion and regional myocar-
ial function. Indeed, severe diffuse coronary artery spasm
fter both PES and SES was well-documented in clinical
ase reports (50–54). So far, the potential contribution of
uch flow pattern impairment to DES thrombosis is still
nknown. We postulate that this phenomenon would result
n blood flow reduction and exacerbation of nonlaminar
ow within the stented vessel, which likely link to increases
n inflammatory and thrombotic risks (Fig. 2).
he Newer Generation of DES
lthough 1st-gen DES have resulted in unquestioned
eductions in in-stent restenosis, long-term safety issues
ave arisen, demanding further reconciliation of the key
roperties of deliverability, efficacy, and safety. To avoid
hese undesirable and potentially devastating side-effects,
iocompatible and bioabsorbable polymers, as well as
olymer-free DES have been developed. Bioabsorbable
tents, both polymeric and metallic, have also been designed
o decrease potential late complications.
Zotarolimus is a tetrazole-containing macrocyclic immu-
osuppressant that has extremely low water solubility. The
ndeavor stent (zotarolimus-eluting stent [ZES], Medtronic
orporation, Minneapolis, Minnesota) is composed of a
obalt alloy and contains 10-g zotarolimus/mm stent
ength with a novel biocompatible phosphorylcholine poly-
er. Hamilos et al. (55) examined the influence of BMS
nd DES on endothelium-dependent vasomotion. SES and
ES caused blunted or absent vasodilation, respectively. In
ontrast, ZES and biolimus-eluting stents (BES) (Terumo
orporation, Tokyo, Japan) exhibited vasodilatory re-
ponses similar to those of BMS. Endothelium-dependent
oronary vasoconstriction was not associated with abnormal
ystemic markers of endothelial inflammation and showed
o relation to in-stent late lumen loss. The authors con-
luded that 1st-gen DES seem to cause ED of the im-
lanted coronary vessel, whereas newer generation DES,
uch as ZES and BES, demonstrated preserved endothelial-
ependent vasomotion at comparable time points, similar to
MS. Similarly, other recently published studies (56–58)
omparing coronary endothelial function between ZES and
ES reported that the latter group demonstrated abnormal
oronary vasoconstriction at the long distal portion of the
reated vessel, as late as at 6 to 9 months of follow-up.
onversely, no significant impairment of vasomotor func-
ion was observed with ZES. Haraguchi et al. (59) evaluated
NOS mRNA expression and vascular function of ZES and
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1175oth the 1st-gen DES at 1 and 3 months in a porcine
odel. Both proximal and distal stented segments of ZES
xpressed significantly more eNOS mRNA than either
ES. Both SES- and PES-implanted vessels exhibited
asoconstriction in response to ACh as compared with ZES
t 1 month in this experimental setting. Although ZES
estores ED, the late luminal loss compared with that seen
n SES is slightly higher in low-risk patient populations.
herefore, endothelial impairment may represent a local
ffect related to the implantation of specific DES brand
ypes (55–59).
The everolimus-eluting stent (EES) (Xience, Abbott
orporation, Abbott Park, Illinois) is loaded with another
nalogue of rapamycin and was designed for enhanced
exibility. This 2nd-gen DES features thin cobalt-
hromium struts and a potentially more biocompatible
uoropolymer. Joner et al. (60) analyzed the endothelial
urface coverage in various polymeric DES using a well-
haracterized rabbit iliofemoral artery model. Endothelial
overage between struts occurred more rapidly than above
truts, where differences in the various stent platforms were
ost notable at 14 days. EES and BMS control stents
howed a greater extent of endothelial coverage above struts
elative to ZES, PES, and SES at 14 days. BES is a 2nd-gen
ES using a bioresorbable polymer (polylactic acid) from
hich biolimus A9, an analogue of sirolimus, is eluted.
All studies to date point toward less ED and faster endo-
Poor heal
Endothe
dysfunct
SES
PES
exposur
Chronic inflammation
Hypersensitivity
Leukocyte ad
Leukocyte ac
Platelet recru
Figure 2. Unified Hypothesis of Vascular Endothelial Dysfunction With the
Abbreviations as in Figure 1.helial structural recovery with the newer DES compared with ehe 1st-gen DES. Although the reasons for this observation
ave not been fully elucidated, several previous studies suggest
ossible clues. While all newer DES contain agents belonging
o the limus family (biolimus, everolimus, and zotarolimus),
imilar to sirolimus, they all differ from SES in release kinetics
nd stent platforms. Zotarolimus and biolimus A9 are more
ipophilic drugs than sirolimus and quickly bind to the target,
ipid-rich tissue on release. This action may result in a more
ocalized effect and reduced systemic drug exposure. Moreover,
iolimus is present only on the vessel side (abluminally) and
hus has minimal penetration into the peripheral circulation.
dditionally, the controlled drug release is characterized by a
mall initial burst followed by sustained simultaneous drug
elease and polymer degradation over 6 months, resulting in
ower drug concentration in the surrounding tissue. Although
he polymer in the SES platform has been associated with
brin deposition and late hypersensitivity reactions, the
iocompatible phosphorylcholine and fluoropolymer coat-
ngs incorporated into ZES and EES, respectively, have
emonstrated in vitro resistance to fibrinogen adsorption.
dditionally, the newer polymers are associated with de-
reased platelet and monocyte activation. Improved stent
esigns with thinner struts, more biocompatible polymers,
r complete elimination of polymers will likely have a
rofound impact on drug elution profiles, endothelial cov-
rage, and functional recovery. Further studies are needed to
larify the mechanisms and relative benefits of these differ-
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1176uture Bio-Active, Pro-Healing, and
ro-Endothelialization Stents
he ability of the endothelium to self-repair is dependent upon
oth the migration of surrounding mature EC and the attrac-
ion and adhesion of circulating EPC to the injured region.
he EPC, in turn, differentiate into endothelial-like cells.
ndovascular therapy with DES interrupts this natural re-
ponse. Accelerating the re-endothelialization of the damaged
rterial segment after stent implantation is an attractive means
o hasten the natural process of healing. DES with such
eneficial properties may result in reduction of neointimal
yperplasia and LST. Studies are on-going to identify agents
hat augment the mobilization and recruitment of EPC to the
njured area (statins, exercise, estrogen, and cytokines). Other
nvestigations have evaluated seeding stents with EC and/or
PC. The Genous Bio-engineered R stent (Orbus Neich, Fort
auderdale, Florida) is a stainless steel bio-engineered stent,
oated with antibodies specific to CD34 to capture circulat-
ng EPC derived from bone marrow.
In their study evaluating an eNOS gene-eluting stent,
harif et al. (61) used a phosphorylcholine-coated stent for
denovirus-mediated gene delivery to the vessel wall. The
ata demonstrated a significant acceleration of re-
ndothelialization in the eNOS-stented vessels as early as 14
ays and persisted for more than 28 days. Another report
62) evaluated the effects of heptapeptide angiotensin-(1-7)
nfusion on vasodilation in rat thoracic aorta and found
mprovement of endothelial function after chronic
ngiotensin-(1-7) infusion.
onclusions
egardless of the mechanisms of vasomotor dysfunction
fter DES deployment, the following questions remain:
hat are the clinical implications and potential remedies?
ne consistent finding in most long-term follow-up anal-
ses of DES versus BMS is the lack of improvement in the
ard outcomes of death and myocardial infarction (63).
ndeed, in some studies, the mortality risk of DES appears
reater than would be expected from stent thrombosis (64).
t is unknown whether the now well-documented phenom-
non vasomotor dysfunction imparts any clinical risk.
resent data suggest less ED and faster endothelial struc-
ural recovery with the newer DES compared with SES and
ES. Therefore, further insight into the mechanisms and
uration of SES- and PES-associated paradoxical constric-
ion are needed. Whether ED in this setting will adversely
ffect prognosis, as has been shown in other clinical contexts
65), as well as the effects of approaches manipulating
ndothelial response, are to be determined.
In summary, the optimal DES should have minimal
mpact on EC structural and functional recovery along withaximal inhibitory effect on SMC proliferation and migra-ion. Utilization of novel imaging modalities such as optical
oherence tomography might help identify the time course
f neointimal formation and any correlation with ED.
mproved clinical efficacy and safety of the second genera-
ion stents awaits longer-term follow-up.
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